Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shibao Feng

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Leukemia & Lymphoma|September 23, 2017
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR studyHartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, et al.
Alimentary Pharmacology & Therapeutics|September 18, 2023
Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitisNaim Alkhouri, Donald Lazas, Rohit Loomba, et al.
Journal of Hematology & Oncology|May 13, 2020
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter studyWei Xu, Shenmiao Yang, Keshu Zhou, et al.
Journal of the National Cancer Institute|February 26, 2015
Primary tumor location as a prognostic factor in metastatic colorectal cancerFotios Loupakis, Dongyun Yang, Linda Yau, et al.
Nature Medicine|June 24, 2023
The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trialDeepak L Bhatt, Harold E Bays, Michael Miller, et al.
The Lancet. Oncology|August 28, 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, et al.
The New England Journal of Medicine|June 25, 2023
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASHRohit Loomba, Arun J Sanyal, Kris V Kowdley, et al.
Haematologica|October 15, 2020
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletionConstantine S Tam, Tadeusz Robak, Paolo Ghia, et al.
The Lancet. Oncology|December 17, 2015
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyMeletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Leukemia & Lymphoma|September 23, 2017
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR studyHartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, et al.
Alimentary Pharmacology & Therapeutics|September 18, 2023
Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitisNaim Alkhouri, Donald Lazas, Rohit Loomba, et al.
Journal of Hematology & Oncology|May 13, 2020
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter studyWei Xu, Shenmiao Yang, Keshu Zhou, et al.
Journal of the National Cancer Institute|February 26, 2015
Primary tumor location as a prognostic factor in metastatic colorectal cancerFotios Loupakis, Dongyun Yang, Linda Yau, et al.
Nature Medicine|June 24, 2023
The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trialDeepak L Bhatt, Harold E Bays, Michael Miller, et al.
The Lancet. Oncology|August 28, 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, et al.
The New England Journal of Medicine|June 25, 2023
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASHRohit Loomba, Arun J Sanyal, Kris V Kowdley, et al.
Haematologica|October 15, 2020
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletionConstantine S Tam, Tadeusz Robak, Paolo Ghia, et al.
The Lancet. Oncology|December 17, 2015
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyMeletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, et al.
Pageof 3